DAVID W. GRYSKA - 10 Jan 2023 Form 4 Insider Report for Forte Biosciences, Inc. (FBRX)

Role: Director
Signature: /s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact
Issuer symbol: FBRX
Transactions as of: 10 Jan 2023
Net transactions value: $0
Form type: 4
Filing time: 12 Jan 2023, 15:05:31 UTC
Previous filing: 21 Nov 2022
Next filing: 15 Feb 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	FBRX	Stock Option (right to buy)	Award	$0	+50,000		$0.000000	50,000	10 Jan 2023	Common Stock	50,000	$1.02	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the thirty six (36) months following the Date of Grant, such that the shares subject to the option shall be fully vested on the third (3rd) anniversary of the Date of Grant. "Date of Grant" shall mean January 10, 2023.

Content

Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the thirty six (36) months following the Date of Grant, such that the shares subject to the option shall be fully vested on the third (3rd) anniversary of the Date of Grant. "Date of Grant" shall mean January 10, 2023.